| PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients A D'incecco, M Andreozzi, V Ludovini, E Rossi, A Capodanno, L Landi, ... British journal of cancer 112 (1), 95-102, 2015 | 640 | 2015 |
| HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients V Martin, L Landi, F Molinari, G Fountzilas, R Geva, A Riva, P Saletti, ... British journal of cancer 108 (3), 668-675, 2013 | 170 | 2013 |
| Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial L Landi, R Chiari, M Tiseo, F D'Incà, C Dazzi, A Chella, A Delmonte, ... Clinical cancer research 25 (24), 7312-7319, 2019 | 155 | 2019 |
| Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer G Minuti, F Cappuzzo, R Duchnowska, J Jassem, A Fabi, T O’brien, ... British journal of cancer 107 (5), 793-799, 2012 | 131 | 2012 |
| Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer L Landi, F D’Incà, A Gelibter, R Chiari, F Grossi, A Delmonte, A Passaro, ... Journal for immunotherapy of cancer 7, 1-9, 2019 | 112 | 2019 |
| First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status F Facchinetti, G Mazzaschi, F Barbieri, F Passiglia, F Mazzoni, R Berardi, ... European Journal of Cancer 130, 155-167, 2020 | 111 | 2020 |
| Sequential use of sorafenib and sunitinib in advanced renal‐cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases C Porta, G Procopio, G Cartenì, R Sabbatini, A Bearz, I Chiappino, ... BJU international 108 (8b), E250-E257, 2011 | 111 | 2011 |
| Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer E Bajetta, I Floriani, M Di Bartolomeo, R Labianca, A Falcone, ... Annals of oncology 25 (7), 1373-1378, 2014 | 106 | 2014 |
| Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer A Fontana, L Galli, A Fioravanti, P Orlandi, C Galli, L Landi, S Bursi, ... Clinical Cancer Research 15 (15), 4954-4962, 2009 | 106 | 2009 |
| Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study F Zustovich, L Landi, G Lombardi, C Porta, L Galli, A Fontana, D Amoroso, ... Anticancer research 33 (8), 3487-3494, 2013 | 105 | 2013 |
| Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab … A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ... Journal for immunotherapy of cancer 9 (4), 2021 | 95 | 2021 |
| Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer R Califano, L Landi, F Cappuzzo Drugs 72, 28-36, 2012 | 91 | 2012 |
| microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers P Gasparini, L Cascione, L Landi, S Carasi, F Lovat, C Tibaldi, G Alì, ... Proceedings of the National Academy of Sciences 112 (48), 14924-14929, 2015 | 84 | 2015 |
| HER2 and lung cancer L Landi, F Cappuzzo Expert review of anticancer therapy 13 (10), 1219-1228, 2013 | 80 | 2013 |
| Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression≥ 50%: a multicenter study with external validation A Cortellini, B Ricciuti, M Tiseo, E Bria, GL Banna, JGJV Aerts, F Barbieri, ... Journal for immunotherapy of cancer 8 (2), 2020 | 75 | 2020 |
| Blockage of interleukin-1β with canakinumab in patients with Covid-19 L Landi, C Ravaglia, E Russo, P Cataleta, M Fusari, A Boschi, ... Scientific reports 10 (1), 21775, 2020 | 73 | 2020 |
| Differences in carbohydrate tolerance in Turner syndrome depending on age and karyotype A Cicognani, L Mazzanti, D Tassinari, A Pellacani, A Forabosco, L Landi, ... European journal of pediatrics 148, 64-68, 1988 | 70 | 1988 |
| Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50% A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ... Cancer Immunology, Immunotherapy 69, 2209-2221, 2020 | 69 | 2020 |
| MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies F Cappuzzo, A Sacconi, L Landi, V Ludovini, F Biagioni, A D'Incecco, ... Clinical colorectal cancer 13 (1), 37-45. e4, 2014 | 65 | 2014 |
| ROS1-rearranged non–small-cell lung cancer is associated with a high rate of venous thromboembolism: analysis from a phase II, prospective, multicenter, two-arms trial (METROS) R Chiari, B Ricciuti, L Landi, AM Morelli, A Delmonte, G Spitaleri, ... Clinical Lung Cancer 21 (1), 15-20, 2020 | 63 | 2020 |
